Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Arlington, Virginia Clinical Trials

A listing of Arlington, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (1713) clinical trials

dorsaVi Back Pain and Movement Registry

The first phase of the study will use a non-randomized two-group prospective longitudinal study design (Group A subjects with LBP, Group B subjects without LBP). The second phase of the study will use a single-group prospective longitudinal study design (Group A, subjects with low back pain). A timeline and step-by-step ...

Phase N/A

1.03 miles

Learn More »

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee Hip or Shoulder Replacement

A4091064 is a long-term observational follow up study of subjects from tanezumab interventional studies A4091056, A4091057 or A4091058.

Phase

1.46 miles

Learn More »

Development of the ERA-Microbiome Non-invasive Diagnosis Tool

Embryonic implantation is a critical process to the survival of the species, that is relatively inefficient especially in humans. Key elements are the embryo, the maternal endometrium, and the cross-communication between them using different scientific perspectives. Endometrial receptivity describes the phenotype that allows embryo adhesion and placentation to occur. Due ...

Phase N/A

1.46 miles

Learn More »

Lyme Test Indication Combinations (LyTIC) Study

The present study aims to investigate the performance characteristics of both established and new assays for Borrelia burgdorferi infection and to assess the relative performance of appropriate combinations of these tests. The study will also investigate the effect of the time course of the infection and its treatment on the ...

Phase N/A

2.1 miles

Learn More »

Influence of Vorapaxar on Thrombin Generation and Coagulability

This investigation will be conducted in patients 18-75 years of age with multiple coronary artery disease risk factors (antiplatelet nave patients) and patients with prior MI or PVD on antiplatelet therapy. Pharmacodynamics will be assessed at multiple time points to assess onset-, maintenance-, and offset-effect of vorapaxar on thrombin generation, ...

Phase

2.1 miles

Learn More »

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

This study is a Phase 1b, open label, multi center, multi-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended dose for phase 2 (RP2D) investigations of PF- 05082566 in combination with KW-0761 (mogamulizumab) in patients with advanced solid tumors. Once the MTD of PF-05082566 administered ...

Phase

2.15 miles

Learn More »

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

The primary objectives of this study are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of tirabrutinib (ONO/GS-4059) in combination with other targeted anti-cancer therapies in adults with relapsed or refractory B-cell lymphoproliferative malignancies. This study consists of two parts: Dose Escalation and Dose Expansion. During the ...

Phase

2.15 miles

Learn More »

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of taselisib given in combination with enzalutamide: Assessment of dose limiting toxicities (DLTs) during the first 4 weeks of treatment (cycle 1). (Phase Ib) II. To determine the safety and tolerability of taselisib given in combination with enzalutamide: Determination of the ...

Phase

2.15 miles

Learn More »

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney

A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of BB3 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney. The major objective is to demonstrate the safety and efficacy of BB3 in reducing the severity of delayed graft function (DGF) in recipients at ...

Phase

2.15 miles

Learn More »

VX15/2503 Treatment for Huntington's Disease

VX15/2503-N-131 is a Phase 2, multi-center, randomized, double-blind, placebo controlled study of VX15/2503 in subjects with late prodromal and early manifest Huntington's disease. The primary objective is to evaluate the safety and tolerability of monthly IV administration of a single dosage of VX15/2503 (or placebo). Efficacy endpoints include determining the ...

Phase

2.15 miles

Learn More »